natgillin/translations-raw huggingface dataset:
The method of claim 36, wherein the plurality of polypeptide compositions comprises different polypeptides. 
Postupak prema patentnom zahtjevu 35, naznačen time, da veći broj sastava polipeptida obuhvaća različite polipeptide.
is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 3- to 10-membered cycloalkyl, 5- to 10-membered heterocyclyl or 5- to 12- membered heteroaryl, each of which is unsubstituted or substituted; 
je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, 3-člani do 10-člani cikloalkil, 5-člani do 10-člani heterociklil ili 5-člani do 12-člani heteroaril, a svaki je nesupstituiran ili supstituiran;
Toilet basket for receiving solid preparations comprising: 
WC košarica (1) koja ima krute pripravke, koja sadrži
The composition for use according to claim 5, packaged in blister packages of about 1 to about 20 capsules per sheet. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se pakira u mjehurasta pakiranja od otprilike 1 do otprilike 20 kapsula po kartici.
The double stranded RNAi agent of claim 1 or 28, wherein the ligand is attached to the 3′ end of the sense strand. 
Dvolančano RNAi sredstvo prema bilo kojem od zahtjeva 1 do 5, naznačeno time da je ligand vezan na 3' završetak sense lanca.
STEP A: dissolving a compound of formula (I-S) in an organic solvent, wherein the organic solvent is isopropyl acetate; 
KORAK A: otapanje spoja formule (I-S) u organskom otapalu, pri čemu je organsko otapalo izopropil acetat;
Y′ represents one of the following groups: 
Datum objave europskog patenta:
A delivery system according to claim 20 where the synthetic MMG is administered in combination with one or more vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, TLR and non-TLR agonists, TLR and non-TLR antagonists, peptides, proteins, gene therapy vectors, DNA vaccines, immunomodulators or co-stimulatory molecules. 
Sustav za primjenu prema zahtjevu 20 gdje se sintetički MMG primjenjuje u kombinaciji s jednim ili više cjepiva, antigena, protutijela, citotoksičnih sredstava, alergena, antibiotika, nekodirajućih (antisense) oligonukleotida, TLR 1 ne-TLR agonista, TLR i ne-TLR antagonista, peptida, proteina, vektora za gensku terapiju, DNA cjepiva, imunomodulatora ili kostimulirajućih molekula.
Reactions were run under inert atmosphere and dry conditions unless otherwise stated. 
Reakcije su provođene u inertnoj atmosferi i suhim uvjetima, ako nije drugačije navedeno.
In another embodiment of the sanding element according to the invention, the lamellas 3 and 4 shoud not necessarily be fixed onto a disc-shaped support, but they could also be fixed for example onto a closed belt. 
U jednom drugom ostvarenju elementa za brušenje koji je u skladu s ovim izumom, nije potrebno da lamele 3 i 4 budu učvršćene na nosač koji ima oblik diska, već one mogu biti učvršćene, na primjer, na zatvoreni remen.
Use of HfO2 nanoparticles or HfO2 nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein the density of said HfO2 nanoparticles or the density of said HfO2 nanoparticles' aggregates is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Uporaba nanočestica HfO, ili agregata nanočestica HfO, za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/cm', i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 1 7,5 u fiziološkoj tekućini.
Alternatively, the electrically insulating substrate 201 may be rolled into tubular form, such that the electrically conductive tracks lie on the outside of the electrically insulating substrate (Figure 2e(ii)). 
Električno grijani sustav za pušenje u skladu s patentnim zahtjevom 1, 2 1li 3, naznačen time što se jedna ili više električno vodljivih tračnica (203) nalazi s vanjske strane cijevi od električno izolirajuće podloge (201).
A pharmaceutical composition comprising the oligonucleotide of claim 1 or the vector of claim 11 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća oligonukleotid definiran u bilo kojem od patentnih zahtjeva 1 do 3, ili vektor u patentnom zahtjevu 4 i farmaceutski prihvatljivi nosač.
the citrate buffer at a concentration of about 20 mM, wherein the pH of the formulation is about 6.5. 
citratni pufer u koncentraciji od 20 mM, tako da pH formulacije iznosi 6.5.
The ratio of the first component (i.e. the adjuvant component comprising or consisting of at least one (m)RNA complexed with the polycationic compound) and the second component (i.e. the at least one free mRNA) is selected in the inventive immunostimulatory composition on the basis of the molar ratio of both RNAs to each other, i.e. the (m)RNA of the adjuvant component, being complexed with a polycationic compound) and the at least one free mRNA of the second component. 
Imunostimulacijski pripravak koji sadrži a) komponentu adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK kompleksirane s polikationskim spojem koji je polikationski peptid ili protein, pri čemu je omjer N/P u komponenti adjuvanta u rasponu od 0.3- 4, kao prve komponente, te b) kao drugu komponentu, barem jednu slobodnu mRNK koja kodira barem jedan antigen, naznačen time da je imunostimulacijski pripravak u stanju izazvati ili poboljšati prirođeni i prilagodljiv imunološki odgovor kod sisavca i pri čemu molarni omjer (m)RNK iz komponente adjuvanta a) prema barem jednoj slobodnoj MRNK od druge komponente b) je u rasponu od 0.1:1 do 1:0.01.
In an embodiment, the second carrier frequency (120) is an unlicensed frequency, especially a frequency of the ISM-radio frequency band (Industrial Scientific and Medical radio frequency band). 
Postupak prema zahtjevu 1, pri čemu je druga noseća frekvencija (120) nelicencirana frekvencija, a osobito frekvencija u ISM-radio frekventnom opsegu.
As shown for example in Figure 28, the compound of Formula 11 may be protected as a 7,9-acetal such as with anisaldehyde dimethyl acetal to form a compound of Formula 23 (where R1=R2=Ph; R3=OH; R7=CH3; R8=H; R9=PhOMe in generalized formula Q of Scheme 7). 
Kao što je prikazano, na primjer na slici 28, spoj formule 11 može biti zaštićen kao 7,9-acetal kao npr. s anisaldehid dimetil acetalom da bi se stvorio spoj formule 23 (gdje R;=R,=Ph; R;=OH; R;=CH;; Rz =H; Ro=PhOMe u općoj formuli Q iz sheme 7).
a first composition comprising an immunogenically effective amount of an adenovirus vector, preferably an adenovirus 26 vector, encoding a synthetic HIV envelope protein having the amino acid sequence of SEQ ID NO: 8, preferably SEQ ID NO: 18; 
prvi pripravak koji sadrži imunogeno učinkovitu količinu vektora adenovirusa, poželjno vektor adenovirusa 26, koji kodira sintetski protein ovojnice HIV-a koji ima aminokiselinsku sekvencu SEQ ID NO: 8, poželjno SEQ ID NO: 18;
In an advantageous embodiment according to the present disclosure the neuropathic pain is a central neuropathic pain syndrome. In some examples the central neuropathic pain syndrome is caused by spinal cord injury and/or spinal cord contusion (see example 1 to 3). 
Spoj za upotrebu prema bilo kojem od zahtjeva 1 do 3, naznačen time da se spoj koristi za liječenje periferne i/ili pretežno periferne neuropatske boli ili središnje i/ili pretežno središnje neuropatske boli.
a microcrystalline cellulose in an amount of 180 mg; 
mikrokristaliničnu celulozu količinom od 180 mg;
height of the scrubbing tower: 15-40m 
Datum objave europske prijave patenta:
is C1-C10alkyl, C3-C7cycloalkyl or phenyl-C1-C6alkyl, wherein the phenyl moiety in phenyl or phenyl-C1-C6alkyl is optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, C1-C6alkoxy, amino, mono- and diC1-C6alkylamino; or a pharmaceutically acceptable salt or solvate thereof. 
R? je Ci-Croalkil, C3-Czcikloalkil ili fenil-C;-Cgalkil, pri čemu fenilni dio u fenilu ili fenil-C,-Cgakilu je proizvoljno supstituiran sa 1, 2 ili 3 supstituenta koji su svaki neovisno odabrani od hidroksi, C;-Cgalkoksi, amino, mono- i diCy-Cgalkilamino; ili njihova farmaceutski prihvatljiva soli ili solvat.
Plant growing system according to claim 2, characterized in that referring to the first principle said continuous spiral-like shape is adapted with regards to its curvature to the growth cycle of specific plant varieties and referring to the second principle said first curvature and said further curvature are adapted to the growth cycle of specific plant varieties. 
Sustav za uzgajanje biljaka sukladno zahtjevu 2, naznačen time što je, pozivajući se na prvi princip, navedeni oblik kontinualne spirale, što so tiče njegove krivulje, prilagođen ciklusu rasta specifične biljne vrste i, pozivajući se na drugi princip, navedena prva krivulja i navedena sljedeća krivulja su prilagođene ciklusu rasta specifične biljne vrsto.
The hydration of the 2,3-double bond can be carried out by hydroboration using a borane reagent such as diborane or a borane-ether (e.g. borane-tetrahydrofuran (THF)) to give an intermediate alkyl borane adduct followed by oxidation of the alkyl borane adduct and hydrolysis in the presence of a base. 
Hidriranje 2,3-dvostruke veze se može provesti hidroboriranjem uporabom boran reagensa poput diborana ili boranetera (na primjer boran-tetrahidrofurana (THF)) da bi se dobio intermedijerni alkil boran adukt nakon čega slijedi oksidacija alkil boran adukta i hidroliza u prisutnosti baze.
unblocking the flow communication between the first volume and the second volume inside the enclosure with the at least one blocking unit. 
deblokiranje protočne komunikacije između prvog volumena (V1) i drugog volumena (V2) unutar kućišta s najmanje jednom jedinicom za blokiranje (30).
On the other hand, the invention may comprise the treatment of a rheumatic disease and/or osteoarthritis in combination with at least one further medicament which is preferably selected from the groups of NSAIDs, DMARDs, TNF a inhibitors, IL-6 inhibitors, analgetic agents or combinations thereof. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeni bolesnik bio ili nije bio prethodno liječen oralnim glukokortikoidima s izravnim otpuštanjem, i/ili NSAID-om, DMARD-om, inhibitorom TNFqa, inhibitorom IL-1, inhibitorom IL-6, analgetikom, ili kombinacijama navedenog.
cells (human kidney, ATCC), transiently transfected with 10 ug human RUP25 receptor and 60 ul Lipofectamine (per 15-cm dish), are grown in the dish for 24 hours (75% confluency) with a media change and removed with 10 ml/dish of Hepes-EDTA buffer (20 mM Hepes+10 mM EDTA, pH 7.4). 
A. Priprema RUP25 receptora 293 stanice (ljudskog bubrega, ATCC), transfektirane sa 10 ug humanog RUPS5S receptora i 60 ul Lipofectamina (po 15 cm posudi) su uzgajane u posudici tijekom 24 sata (75%) sa medijem mijenjanim i uklanjanim pomoću 10 ml/posudica Hepes-EDTA pufera (20 mM Hepes + 10 mM EDTA, pH 7.4).
In the particular case where the Group II or Group III salt(s) of an aliphatic carboxylic acid of step (a) is in the form of a dry powder, it is preferable that this salt feature a d98 of 20 microns according to screen residue measurement performed with 20 microns DIN screens. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time da sol odnosno soli Skupine II ili Skupine II C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) se primjenjuju u obliku suhog praha, te poželjno imaju dog od 20 mikrona prema mjerenju ostatka prosijavanja provedenog sa DIN sitima od 20 mikrona.
Example 1.8: Determination of the total amount of lactose 
Datum objave europske prijave patenta:
The fuel gas supply system of a vessel according to claim 1, wherein the second pump (4) compresses the LNG to a pressure of 200 to 300 bar. 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da sredstva za komprimiranje sadrže jednu crpku.
The integrated circuit according to claim 1 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the device by units of RB Gs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
A method for manufacturing a finished tanned leather comprising using the tanned hide of claim 13, wherein said tanned hide is further processed, retanned, dyed, fat liquored and finished so as to obtain a finished tanned leather. 
Postupak proizvodnje dovršene štavljene kože, naznačen time što se sastoji u upotrebi štavljene kože u skladu s patentnim zahtjevom 13, gdje se navedenu štavljenu kožu dodatno obrađuje, preštavljuje, boji, masti 1 dovrši kako bi se dobilo dovršenu štavljenu kožu.
Topical ophthalmic composition selected from the group of eye drops, ointments and unguents, said composition containing somatostatin or a somatostatin analogue selected from the group formed by somatostatin-28, somatostatin-14, somatostatin-13, prosomatostatin, octreotide, lanreotide, vapreotide, pasireotide, seglitide, cortistatin and their pharmaceutically acceptable salts, for use in the treatment and/or prevention of a posterior segment eye disease selected from the group formed by nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, retinal neovascularization, ischemia-induced retinopathy, retinopathy of prematurity, sickle-cell retinopathy, retinal vein occlusion, retinitis pigmentosa, uveitis, macular edema and cystoid macular edema by topical ocular administration, characterized in that the concentration of somatostatin or somatostatin analogue in said composition ranges between 1 µg/mL and 10 mg/mL. 
HR P20160954 T1 PATENTNI ZAHTJEVI Topikalna očna kompozicija izabrana iz grupe koji čine kapi za oči, masti 1 melemi, s time što sadrži somatostatin ili neki analog somatostatina izabran iz grupe koju čine somatostatin-28, somatostatin-14, somatostatin-13, prosomatostatin, oktreotid, lanreotid, vapreotid, pasireotid, seglitid, kortistatin i njihove farmaceutski prihvatljive soli, za primjenu u terapiji iili prevenciji bolesti stražnje očne komore, među kojima su ne-proliferativna dijabetska retinopatija, proliferativna diabetska retinopatija, neovaskularizacija mrežnice, iskemijska retinopatija, retinopatija nedonoščadi, retinopatija uslijed anemije srpastih okluzija retinalne vene, retinitis pigmetnoza, uveitis, otok makule i cistoidni otok makule primjenom topikalnog tretmana, naznačenog time što se koncentracija somatostatina ili analoga somatostatina u toj kompoziciji nalazi u opsegu od I ug/mL do 10 mg/mL.
Ring B is an optionally substituted 5- or 6-membered aryl or heteroaryl ring having zero to three ring nitrogen atoms and optionally one additional ring heteroatom selected from oxygen and sulfur; 
prsten B je izborno supstituirani 5- ili 6-člani aril ili heteroaril prsten koji ima nula do tri atoma dušika u prstenu i izborno jedan dodatni heteroatom u prstenu izabran od kisika i sumpora;
A compound as claimed in any one of claims 1 to 4, or a pharmaceutically acceptable salt, ester or prodrug thereof wherein n is 1, R3 is H and one of R4 and R5 is methyl. 
Spoj prema zahtjevima 1, 6 ili 8, ili njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv ester, ili farmaceutski sastav prema zahtjevu 2 ili 9, naznačen(a) time, da nje 11 R3 je H ijedan od R4 1 R5 je metil.
The single immunoglobulin variable domain antibody of claim 3 or claim 4, comprising the amino acid sequence of SEQ ID NO:543, wherein the PEG is a 30 kD linear PEG, and wherein the PEG polymer is linked to the D70C cysteine residue. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom iz patentnog zahtjeva 3 ili patentnog zahtjeva 4, koje sadrži aminokiselinsku sekvencu sa SEQ ID NO:543, gdje PEG je linearni PEG od 30 kD, i gdje je PEG polimer vezan za D70C cisteinski ostatak.
The pharmaceutical composition of embodiment 47, wherein said isotonizing agent is sodium chloride, said sodium chloride being present in said formulation at a concentration of about 50 mM to about 300 mM. 
Farmaceutski sastav prema zahtjevu 27, naznačen time da je navedeni izotonizirajući agens natrijev klorid, navedeni natrijev klorid je prisutan u navedenoj formulaciji u koncentraciji od oko 50 mM do oko 300 mM.
A composition according to claim 28, which, in addition to comprising the compound of Formula (I), comprises a further herbicide as mixing partner. 
Sastav, prema zahtjevu 30, naznačen time, da dodatno uz sadržaj spoja formule (T) obuhvaća neki drugi herbicid za sudjelovanje u mješavini.
Detailed Description of the Invention 
Detaljan opis ovog izuma
Column 2 of Table A shows IC50 data from Test (a) for the inhibition of EGFR tyrosine kinase protein phosphorylation; column 3 shows IC50 data from Test (a) for the inhibition of erbB2 tyrosine kinase protein phosphorylation; column 4 shows IC50 data for inhibition of proliferation of KB cells in Test (b) described above; and column 5 shows IC50 data for inhibition of phosphorylation of erbB2 in a MCF7 derived cell line in Test (e) described above: 
U stupcu 2 Tablice A prikazane su ICsg vrijednosti iz Testa (a) za inhibiciju fosforilacije proteina EGFR tirozin kinazom; u stupcu 3 prikazane su ICsg vrijednosti iz testa (a) za inhibiciju fosforilacije protine erbB2 tirozin kinazom; u stupcu 4 prikazane su ICsg vrijednosti za inhibiciju proliferacije KB stanica u Testu (b) opisanom u gornjem tekstu; i u stupcu 5 prikazane su ICsg vrijednosti za inhibiciju fosforilacijske aktivnosti erbB2 kinaze u Staničnoj liniji izvedenoj iz MCF7 u gore opisanom Testu (e):
third variant: glycerol in combination with at least one of the compounds set out in point (ii), in the aqueous or pure form 
Postupak prema jednom od zahtjeva 1 ili 3, naznačen time da navedeni aditiv sadrži glicerol u čistom obliku ili kao vodu i glicerol.
Method according to any one of embodiments 1-3, wherein the anti-photogreying additive is present in the photocatalytic dispersion in a range of 1-35 wt.%, preferably 1-15 wt.%, more preferably 1-5 wt.%. 
Postupak prema zahtjevima od 1-3, naznačen time da je aditiv protiv promjene boje pod utjecajem svijetlosti prisutan u fotokatalitičkoj disperziji u rasponu od 1-35% težine, a poželjno je od 1-15% težine, a poželjnije je od 15% težine.
A kit for preparing the composition of any one of embodiments 1 to 15, wherein the kit comprises (i) the lyophilised composition of embodiment 15, and (ii) aqueous material, wherein component (ii) is for reconstituting component (i) in order to provide the aqueous composition. 
Pribor za pripremu sastava prema bilo kojem od zahtjeva 1 do 15, naznačen time da pribor sadrži (i) liofilični sastav prema zahtjevu 16 i (ii) vodeni materijal, pri čemu komponenta (ii) ima ulogu rekonstituiranja komponento (1) kako bi dala vodeni sastav,
The pharmaceutical composition according to claims 4 or 5, wherein the cardiac condition is cardiac arrhythmia, tachycardia, atrial arrhythmia, atrial tachyarrhythmia, atrial fibrillation, sustained atrial fibrillation, non-sustained atrial fibrillation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death or exercise-induced sudden cardiac death. 
Farmaceutska kompozicija prema patentnom zahtjevu 7, naznačena time što je srčano stanje srčana aritmija, tahikardija, atrijalna aritmija, atrijalna tahiaritmija, atrijalna fibrilacija, dugotrajna atrijalna fibrilacija, kratkotrajna atrijalna fibrilacija, ventrikularna artimija, ventrikularna fibrilacija, ventrikularna tahikardija, dugotrajna ventrikularna tahikardija, kratkotrajna ventrikularna tahikardija, kateholaminergička polimorfna ventrikularna tahikardija (CPVT), srčana insuficijencija, iznenadna srčana smrt ili iznenadna srčana smrt izazvana pojačanom fizičkom aktivnošću.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to three CC chemokines selected from the group consisting of CCL3/MIP-1a,CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na tri CC kemokina odabrana iz skupine koju čine CCL3/MIP-1a, CCL4/MIP-1B, i CCL5/RANTES i koji se ne vežu na CCL2/MCP-1.
For example, the vertebrate can have, or be predisposed to developing, an endogenous retinoid deficiency associated with Age-Related Macular Degeneration, Leber Congenital Amaurosis, Retinitis Punctata Albesciens, Congenital Stationary Night Blindness, Fundus Albipunctatus, or other disease or condition associated with an endogenous retinoid deficiency. 
Derivat retinala za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time, da je navedena endogena deficijencija 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnom amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
The materials which are stated below to be suitable for production of the barrier layer may preferably be used for this purpose. 
Pogodno se za ovo mogu primijeniti dolje navedeni materijali, koji su prikladni i za strukturu sloja barijere.
A composition comprising (i) a bacterially derived minicell that contains a drug molecule and (ii) a bispecific ligand that is capable of binding to a surface component of said minicell and to a surface component of a non-phagocytic mammalian cell. 
Kompozicija prema Zahtjevu 1, dobijena postupkom iz Zahtjeva 7, naznačena time, što spomenuta kompozicija sadrži neki bispecifični ligand koji se je u stanju vezati za neku komponentu na površini neke ne-fagocitne stanice sisavaca.
The use of any one of claims 38 to 43, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione is prepared to be administered orally, parenterally, nasally, topically or sublingually. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 38 do 43, naznačena time što se kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion pripravlja za oralnu, parenteralnu, nazalnu, topikalnu ili sublingvalnu primijenu.
Apparatus according to any of claims 5 to 7, wherein the predetermined neighborhood comprises at least one position vertically adjacent to the current first-type syntax element. 
Uređaj prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se blok koeficijenata transformacije odnosi na sadržaj duboke mape.
detecting the presence of anti-ligand in the sample. 
(b) otkrivanje prisutnosti anti-ligand u uzorku.
In this situation buprenorphine was behaving as an opiate agonist of low intrinsic activity. 
U toj situaciji buprenorfin se ponašao kao opijatni agonist niskog intrinzičnog djelovanja.
The method of any of claims 11 to 13, further comprising the step of reacting 2-amino-6-nitrobenzoic acid with an activated acetic acid in a solvent to form 2-methyl-5-nitro-4 H- benzo[d][1,3]oxazin-4-one before reacting 2-methyl-5-nitro- 4H- benzo [d][1,3]oxazin-4-one with 3-aminopiperidine-2,6-dione or a salt thereof; preferably wherein the activated acetic acid is acetyl chloride, or acetic anhydride. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što dodatno uključuje korak reakcije 2-amino-6-nitrobenzojeve kiseline s aktiviranom octenom kiselinom u otapalu kako bi se dobilo 2-metil-5-nitro-4H-benzo[d][1,3]oksazin-4-on, prije reakcije 2-metil-5-nitro-4H-benzo[d][1,3]oksazin-4-ona s 3-aminopiperidin-2,6-dionom, ili njegovom solju; po mogućnosti gdje je aktivirana octena kiselina acetil-klorid ili acetanhidrid.